Thyroid Cancer Research Results and Study Updates
See Advances in Thyroid Cancer Research for an overview of recent findings and progress, plus ongoing projects supported by NCI.
-
Why Have Thyroid Cancer Diagnoses Spiked for US Women?Posted:
Women are far more likely than men to be diagnosed with small thyroid cancers that probably would have never caused problems during their lifetime, a new study finds. The results may help explain why thyroid cancer seems to be more common in women.
-
Selpercatinib Approved for Thyroid and Lung Cancers with RET Gene AlterationsPosted:
FDA has granted accelerated approval for selpercatinib (Retevmo) to treat certain patients with thyroid cancer or non-small cell lung cancer whose tumors have RET gene alterations. The drug, which works by blocking the activity of RET proteins, was approved based on the results of the LIBRETTO-001 trial.
-
Genomic Test Helps Identify Thyroid Nodules That Don’t Require SurgeryPosted:
The test measures genomic changes in thyroid biopsy samples and generates a score based on how strongly each change is associated with thyroid cancer. A study showed the test accurately identified samples that, after surgery, were found to be benign.
-
Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid CancerPosted:
FDA recently approved the targeted-drug combination to treat patients with advanced melanoma and a subset of patients with a rare and aggressive form of thyroid cancer whose tumors have a specific mutation in the BRAF gene.
-
Patients Who Choose No Intervention for Small Thyroid Cancers Report Lack of SupportPosted:
Patients who choose not to pursue immediate biopsy or treatment for small, asymptomatic thyroid cancers, or suspected cancers, can experience a lack of support from doctors and loved ones, a new study shows.
-
After Rising for Decades, Thyroid Cancer Incidence StabilizesPosted:
After rising steadily since the 1990s, the incidence of thyroid cancer in the United States may be leveling off, according to an analysis of data from NCI’s SEER program.
-
FDA Approves Lenvatinib for Radioactive Iodine-Refractory Thyroid CancerPosted:
The FDA has approved lenvatinib (Lenvima) to treat some patients with the most common type of thyroid cancer.